Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Nov 1;40(42):3486-3493.
doi: 10.1093/eurheartj/ehz392.

Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial

Affiliations
Clinical Trial

Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial

Pranav S Garimella et al. Eur Heart J. .

Abstract

Aims: Biomarkers of kidney tubule injury, inflammation and fibrosis have been studied extensively and established as risk markers of adverse kidney and cardiovascular disease (CVD) outcomes. However, associations of markers of kidney tubular function with adverse clinical events have not been well studied, especially in persons with chronic kidney disease (CKD).

Methods and results: Using a sample of 2377 persons with CKD at the baseline Systolic Blood Pressure Intervention Trial (SPRINT) visit, we evaluated the association of three urine tubular function markers, alpha-1 microglobulin (α1m), beta-2 microglobulin (β2m), and uromodulin, with a composite CVD endpoint (myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure, or death from cardiovascular causes) and mortality using Cox proportional hazards regression, adjusted for baseline estimated glomerular filtration rate (eGFR), albuminuria, and CVD risk factors. In unadjusted analysis, over a median follow-up of 3.8 years, α1m and β2m had positive associations with composite CVD events and mortality, whereas uromodulin had an inverse association with risk for both outcomes. In multivariable analysis including eGFR and albuminuria, a two-fold higher baseline concentration of α1m was associated with higher risk of CVD [hazard ratio (HR) 1.25; 95% confidence interval (CI): 1.10-1.45] and mortality (HR 1.25; 95% CI: 1.10-1.46), whereas β2m had no association with either outcome. A two-fold higher uromodulin concentration was associated with lower CVD risk (HR 0.79; 95% CI: 0.68-0.90) but not mortality (HR 0.86; 95% CI: 0.73-1.01) after adjusting for similar confounders.

Conclusion: Among non-diabetic persons with CKD, biomarkers of tubular function are associated with CVD events and mortality independent of glomerular function and albuminuria.

Keywords: Alpha-1 microglobulin; Beta-2 microglobulin; Biomarkers; Cardiovascular disease; Chronic kidney disease; Tubular function; Uromodulin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Unadjusted incidence rates of composite cardiovascular disease events and mortality across quartiles of tubular function biomarkers. Each point in the figure depicts the unadjusted incidence rates for composite cardiovascular disease events per quartile of biomarker. The lines on either side of the points represent the standard error bars for the incident rate.
Take home figure
Take home figure
Comparison of the association of between estimated glomerular filtration rate, albumin–creatinine ratio, and tubular function biomarkers with composite cardiovascular disease events and all-cause mortality. The figure compares the HRs of composite cardiovascular disease and all-cause mortality per 1 SD change in each of the three tubular function biomarkers levels, estimated glomerular filtration rate, and albuminuria in baseline SPRINT participants with CKD. Uromodulin and estimated glomerular filtration rate are plotted as per 1 SD lower, while alpha-1 microglobulin, beta-2 microglobulin, and urine albumin are per 1 SD higher. All tubular function biomarkers, estimated glomerular filtration rate, and albuminuria are included in the same model and adjusted for all the variables listed in Model 3 in the preceding tables and text.
None

Comment in

References

    1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease HBPRCC, Epidemiology, Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154–2169. - PubMed
    1. Driver TH, Katz R, Ix JH, Magnani JW, Peralta CA, Parikh CR, Fried L, Newman AB, Kritchevsky SB, Sarnak MJ, Shlipak MG; on behalf of the Health ABC Study. Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Kidney Dis 2014;64:49–56. - PMC - PubMed
    1. Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X, Mifflin T, Waikar SS, Sabbisetti VS, Bonventre JV, Coresh J, Nelson RG, Kimmel PL, Kusek JW, Rahman M, Schelling JR, Vasan RS, Liu KD; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators; CKD Biomarkers Consortium. Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death: the CRIC study. Clin J Am Soc Nephrol 2017;12:761–771. - PMC - PubMed
    1. Liu KD, Yang W, Go AS, Anderson AH, Feldman HI, Fischer MJ, He J, Kallem RR, Kusek JW, Master SR, Miller ER, Rosas SE, Steigerwalt S, Tao K, Weir MR, Hsu CY, Investigators CS.. Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2015;65:267–274. - PMC - PubMed
    1. Akerstrom B, Logdberg L, Berggard T, Osmark P, Lindqvist A.. alpha(1)-microglobulin: a yellow-brown lipocalin. Biochim Biophys Acta 2000;1482:172–184. - PubMed

Publication types

MeSH terms